Additional research from the vaccine manufacturers would be needed to support any changes to the dosing schedule.
Researchers provide reassurance regarding potential allergic reactions to mRNA COVID-19 vaccinations from Pfizer and Moderna.
Study authors measured the levels of immunoglobulin M, IgG, and IgA in healthcare workers, and observed fast decay of 2 antibodies which has implications for further seroprevalence studies.
In addition to 2 COVID-19 vaccines, the FDA approved multiple medications of import to nurse practitioners and physician assistants.
The AAAAI, ACAAI, and the CSACI have published a consensus statement and recommendations on nutritional interventions for the prevention of food allergy.
There has been a 10% decline in young children receiving their first measles/mumps/rubella (MMR) vaccination by age 16 months.
AstraZeneca assessed the immunogenicity, safety, and efficacy of their novel chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1 nCoV-19.
Seventy-one percent of the US public report that they would get a COVID-19 vaccine, marking an increase from 63% in September.
For patients with high-risk CVD, high-dose trivalent inactivated influenza vaccination does not reduce cardiopulmonary hospitalization or all-cause mortality.
Human papillomavirus (HPV) vaccines are safe and well tolerated in male patients, with few reports of adverse events.
Older adults are less likely to get a COVID-19 vaccine than a flu vaccine, according to the University of Michigan National Poll on Healthy Aging.
To facilitate harmonized evaluation and comparison of the efficacy of COVID-19 vaccines, study authors proposed a general set of clinical endpoints, along with considerations to guide the selection of primary endpoints.
The national organ shortage has led researchers to criticallyre-evaluate organ sources that previously were considered toorisky for HIV patients.
Study authors identified and evaluated a statistical signal for an increased risk of Guillain-Barré Syndrome in days 1-42 after 2018-2019 high-dose influenza vaccine administration.
The effect of coronavirus disease 2019 (COVID-19) on patients with food allergy and their parents and caregivers is substantial.
Three interventions for increased human papillomavirus vaccine coverage are cost-effective.
The much-awaited remedy to the widespread transmission of SARS-CoV-2 comes with many logistical caveats.
A total of 131 cases of COVID-19 were reported in the interim analysis, with no hospitalizations or severe cases noted in participants who received the vaccine.
The placebo-controlled COVE study is investigating the efficacy and safety of mRNA-1273 at the 100mcg dose (given intramuscularly in a 2-dose series, approximately 28 days apart) in more than 30,000 adults aged 18 years and older.
The trial will continue as planned and final analysis is expected when the number of confirmed COVID-19 cases reaches 164.